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Abstract. The use of 5α‑reductase inhibitors (5α‑RIs) as prostate cancer chemoprevention agents is controversial. Two large
randomized trials, the Prostate Cancer Prevention Trial (PCPT)
and the Reduction by Dutasteride of Prostate Cancer Events
(REDUCE) Trial, have both shown a decreased incidence of
prostate cancer in patients administered with 5α‑RIs. Both
studies showed, however, an increased risk of higher‑grade
prostate cancer. Numerous studies have since analyzed the
inherent biases in these landmark studies and have used mathematical modeling to estimate the true incidence of prostate
cancer and the risk for high‑grade prostate cancer in patients
undergoing 5α‑RI treatment. All primary publications associated with the PCPT and REDUCE studies were reviewed
in detail. Pertinent references from the above publications
were assessed and a literature search of all published articles
associated with PCPT, REDUCE or 5α‑RIs as chemopreventative agents through October 2013 was performed using
Pubmed/Medline. PCPT and REDUCE both showed a significant decrease in the incidence of prostate cancer following the
administration of 5α‑reductase inhibitor, as compared with
placebo, suggesting that 5α‑RIs may be effective agents for
prostate cancer chemoprevention. Inherent biases in the design
of these two studies may have caused an artificial increase
in the number of high‑grade cancers reported. Mathematical
models, that integrated data from these trials, revealed neither
an increased nor decreased risk of high‑grade disease when
taking these biases into consideration. Moderately strong
evidence exists that 5α‑RIs may reduce the risk of prostate
cancer. PCPT and REDUCE showed a decreased prevalence
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of prostate cancer in patients taking 5α‑RIs. Urologists should
have a working knowledge of these studies and discuss with
patients the risks and benefits of 5α‑RI treatment. Further
studies to evaluate the cost‑effectiveness of chemoprevention
with 5α‑RIs and appropriate patient selection are warranted.
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1. Introduction
Prostate cancer is the second most common cancer among men,
with 206,640 diagnoses and 28,088 prostate cancer‑associated
deaths reported in 2009 (1). The decreased mortality rate of
prostate cancer in the prostate‑specific antigen test (PSA) era
is well‑documented (2). This is widely credited due to the
possibility for earlier diagnosis of the disease, which enables
treatment while the cancer remains localized in the prostate.
With an increased rate in diagnoses of prostate cancer came
concerns of over‑treatment of clinically insignificant tumors
and significant treatment side effects that have put prostate
cancer into the national public health spotlight (3). These
concerns culminated in May 2012 when the United States
Preventative Task Force recommended against the use of PSA
as a screening test for prostate cancer (3).
Prostate cancer has been considered to be an ideal tumor
for chemoprevention due to its multi‑step molecular pathway,
prolonged latent phase and increased incidence with age (4).
Several trials have pursued agents that could decrease the
incidence and/or progression of prostate cancer (4). The
Selenium and Vitamin E Cancer Prevention Trial investigated
the impact of vitamin E and selenium alone and in combination on prostate cancer, and produced unexpected negative
results. There was a reported increase in prostate cancer
incidence in the group receiving vitamin E, while no significant effect was detected in the other groups (5). Recognizing
the tumor‑enhancing effects of an agent that was previously
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reported by a wealth of experimental basic findings as being
chemopreventive, severely challenged the translational significance in a clinical setting (6). The Alpha‑Tocopherol, Beta
Carotene Prevention Trial showed initial promising results for
prostate cancer prevention, but these results did not generate
significance as the study progressed (7). Murine studies of the
selective estrogen receptor modulator toremifene revealed its
potential for delaying prostate cancer progression, but studies
in human subjects have failed to deliver positive results (8).
Other common medications, such as statins and nonsteroidal
anti‑inflammatory drugs, have also been evaluated in numerous
studies with controversial results (6,‑12).
5α‑reductase inhibitors (5α‑RIs) have been among the most
controversial candidates in the search for chemopreventative
agents for prostate cancer; 5α‑reductase converts testosterone to
the intracellular active dihydrotestosterone, with a high affinity
for the androgen receptor (13). Inhibitors of 5α‑reductase
activity are clinically used in the treatment of benign prostatic
hyperplasia, through their ability to decrease the volume of
the prostate gland in aging men. There are two isoenzymes of
5α‑reductase: Type 1, which is expressed in the liver and skin,
and type 2 that is expressed in the prostate (14). Finasteride
(Proscar®) inhibits only the type 2 isoenzyme, but dutasteride
(Avodart®) inhibits both the type 1 and type 2 isoenzymes.
While the fundamentally significant contribution of androgens
to prostate cancer etiology and progression had long been the
focus of intense molecular exploitation, there had been no
clinical trial to investigate the role and effects of 5α‑reductase in
prostate cancer in humans (15). The PCPT and REDUCE trials
were designed to investigate the effect of finasteride (PCPT)
and dutasteride (REDUCE) on the incidence of prostate cancer.
Despite polarizing designs and differences in the composition
of patient populations enrolled in the studies, the overall results
and conclusions were analogous, simultaneously raising hope
and concern for the use of 5α‑RIs in the treatment of prostate
cancer. This review aims to evaluate these two landmark clinical
trials within the framework of the current debate, and reviews
pertinent studies regarding the use of targeting of 5α‑reductase
for prostate cancer chemoprevention through October 2013.
2. Trials of prevention, PCPT vs. REDUCE: Prostate cancer finds its ‘groove’
Data from the PCPT were published in July 2003 in the New
England Journal of Medicine (16). This study tested whether
lowering circulating androgen levels in the prostate could
reduce the risk of developing prostate cancer. Inclusion criteria
were males aged ≥55 years old with PSA levels ≤3.0 ng/ml and
a normal digital rectal examination (DRE) result. Patients who
were randomized had annual PSA/DRE tests, semi‑annual
clinic visits and quarterly telephone follow‑up calls. A prostate
biopsy was recommended for those exhibiting a PSA >4.0 ng/ml
or abnormal DRE, and the majority of biopsies performed were
6‑core biopsies. An adjustment factor of 2.3 was applied to the
treatment arm to account for the biological impact of finasteride
on lowering the serum PSA values, and to maintain an equivalent
number of biopsies in the placebo group. The study, originally
planned for a 7‑year duration, was terminated 15 months early
due to meeting the objectives of the study ahead of schedule. A
significant decrease in the prevalence of prostate cancer in the

finasteride‑treated group, as compared with the placebo group
(18.4 vs 24.4%, P≤0.001), was observed. The impact of these
data was reduced due to the observations that of the patients
diagnosed with prostate cancer, an increased number of patients
were found to have high‑grade tumors (Gleason 7‑10) in the
finasteride‑treatment group, as compared with the placebo
group (37 and 22% respectively, P<0.001). Subsequently, this
led to speculation among patients, urologists, epidemiologists
and health policy makers as to whether or not finasteride,
previously presented as an attractive chemoprevention agent for
prostate cancer, was predisposing patients to a more aggressive
disease, thus compromising treatment outcomes upon prostate
cancer diagnosis.
The REDUCE trial was designed to recruit men at an
increased risk for prostate cancer with no evidence of the
disease at baseline (17). Initial results of the REDUCE trial
were published in the New England Journal of Medicine in
April 2010 with great anticipation of the radical effect on
blocking 5α‑reductase action upon the initiation of malignant
prostate growth (18). The study was planned for 4 years of
follow‑up, and protocol biopsies were planned at 2 and 4 years
in efforts to minimize the ‘for cause’ biopsies. These biopsies
were performed at the discretion of the clinician, likely based
on elevated PSA levels or an abnormal DRE, but this was not
explicitly defined in the study. The biopsies were obtained on an
as‑needed basis, between the 2 and 4 year scheduled biopsies.
Biopsies were to be 10 cores to balance between the need to
maximize the detection of clinically significant tumors, yet
minimize the over-diagnosis of low grade tumors (17).
The primary endpoint of this study was the diagnosis
of prostate cancer by a TRUS biopsy during the study. This
endpoint was examined in several subgroups: Age, family
history of prostate cancer, International Prostate Symptom
Score, prostate volume, PSA level and body mass index. The
incidence of prostate cancer was lower in the dutasteride
arm in every subgroup. During the 4‑year period of the trial,
prostate cancer was diagnosed in 659 (19.9%) patients of the
3,305 patients in the dutasteride arm of the study and 858
(25.1%) of the 3,424 patients in the placebo arm, resulting in
an absolute risk reduction of 5.1% and a relative risk reduction
of 22.8%. The majority of tumors were low grade, with 70%
of the total number of cancers exhibiting a Gleason score of 5
or 6. The number of tumors with Gleason grades of 7‑10 did
not differ significantly over the course of the 4‑year study, or
within the subgroup of biopsies taken at the 1‑ to 2- or 3‑ to
4‑year point. The promise of an absence of a higher number
of tumors with Gleason grade 8‑10 at the end of 1‑2 years in
the dutasteride group, was counteracted by a significant difference detected in the number of tumors with Gleason grade 8‑10
in the later follow‑up (years 3‑4) (12 and 1, dutasteride vs. the
placebo group, respectively, P<0.003). This last finding from the
REDUCE trial likely precipitated the denial by the Food and
Drug Administration for the use of 5α‑RIs as prostate cancer
chemopreventative agents, serving to reiterate the controversial
and apparently analogous results from the PCPT.
3. Discussion
The results of PCPT and REDUCE showed a significant
reduction in the overall incidence of prostate cancer in patients
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administered with 5α‑RIs, but there was an increased incidence
of high grade tumors in the treatment arm of both studies.
Numerous reports have aimed to dissect these two studies and
debate whether or not the results reflect a true increase in incidence of high‑grade tumors or if this is merely the result of an
inherent bias within the studies. Debates have revolved around
the number of patients excluded from the final analysis of the
PCPT, increased sensitivity and specificity of prostate cancer
detection in biopsies on patients in the treatment arms of each
study and inherent selection biases in both studies.
The fact that a large number of patients in the PCPT were
not included in the final analysis for various reasons requires
serious consideration. In the finasteride group, 3,290/8,137
(46.3%) patients were not included in the final analysis due to
death (7.0%), declining end of study biopsy (25.4%), being lost
to follow‑up (8.0%) or being excluded from the final analysis
(5.8%). A similar number of patients were not included in the
placebo group, with 3,016/8,158 (42.4%) patients excluded
due to death (6.7%), declining end of study biopsy (22.8%),
being lost to follow‑up (7.4%) or being excluded from the final
analysis (5.5%). Unanswered questions remain, with >40% of
the data in each group not being included in the final analysis.
Redman et al (19) created a statistical model to account
for the large number of PCPT patients that did not have an
endpoint (19). Covariates, such age, family history and treatment arm assignment were used to predict the outcomes of
these patients (lacking reported outcomes), and such analysis
revealed that prostate cancer prevalence remained significantly
lower in the finasteride group as compared with the placebo
(14.7 vs 21.1%, P<0.0001). There was no significant increase,
however, in the high‑grade cancer detected in the finasteride
group as compared with the placebo (4.8 vs 4.2%, P=0.012).
Another potential bias in these studies is the increased sensitivity and specificity of the prostate biopsy in the treatment arms
of each study. 5α‑RIs are known to decrease prostate volume (20)
and outcomes of the REDUCE trial documented a significant
reduction in the prostate volume in the treatment arms as
compared with controls, with the prostate volume in the placebo
group of the REDUCE trial increasing from a mean of 45.8 ml
at baseline to 52.3 and 56.2 ml at 2 and 4 years, respectively. The
dutasteride group decreased from 45.7 to 38.6 ml, from baseline
to 2 years, and remained stable at 39.0 ml at the 4‑year mark as
expected. Pinsky et al (21) aimed to estimate how this difference
in volume would impact the sensitivity and specificity of prostate biopsy. Towards resolving this issue, a model was created to
extrapolate the pathological findings from radical prostatectomy
specimens and their correlation with biopsy specimens, to those
who did not undergo a prostatectomy, but had been diagnosed
with prostate cancer on biopsy. The misclassification rate (the
rate of tumors that were low‑grade on biopsy but high‑grade
on prostatectomy specimen) was significantly lower in the
finasteride arm (34.6%) as compared with the placebo (52.6%).
Given the low overall number of high‑grade tumors, this could
be underlying the observed increased sensitivity for detecting
high‑grade disease on biopsy in the finasteride arm and a false
increase in true high‑grade cancers in the finasteride group.
Cohen et al (22) also investigated the effect of prostate
volume on high‑grade disease detection. Development of a
logistic regression model based on prostate volume as well
as race, family history, age and number of biopsy cores,
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indicated that the association of gland volume and detection
of high‑grade cancer existed independently of the drug effect.
A second model designed to predict an odds ratio for low- and
high‑grade disease, revealed no difference in the high‑grade
disease between the finasteride and placebo groups after
volume adjustment. Similarly, Kaplan et al (23) created a
logistic regression model that adjusted the results based on the
sampling density of biopsies in the PCPT. They showed that
finasteride significantly reduced the risk of prostate cancer relative to the placebo, across multiple groups of prostate cancer
(Gl 4‑7), with no significant effect on Gl 2‑3 or 8‑10 prostate
cancer groups (23). Another model integrating the varying
sensitivity of prostate biopsies and its potential effect on prostate cancer detection (19), revealed a risk of high‑grade disease
either equivalent to or less than the placebo in the finasteride
arm. Biopsy sensitivity was shown to have to be >85% in the
placebo group and 25‑30% in the finasteride group for there to
be a significant increase in high‑grade disease in the finasteride
group, based on these models. This combination seems highly
unlikely given that finasteride can increase the sensitivity
for detection of high‑grade tumors. This evidence implicates
inherent biases in the PCPT trial design being responsible for
the observed increase in high‑grade tumors in the treatment
arm, thus specifically illustrating how small changes in biopsy
sensitivity could explain observed increased risk of high‑grade
prostate cancer.
Recognition of the role of selection bias in the PCPT trial
undermining the selection of patients for prostate biopsy may
provide a constructive platform. Despite the attempt to have an
even number of biopsies in each group by adjusting the PSA in
the treatment arm by 2.3 (vs. 2), recommendations for biopsy
were higher in the placebo group (24.8%) as compared with
finasteride treatment (22.5%). A significantly lower number
of men (P<0.001) underwent a biopsy for elevated PSA in
the finasteride group (48.4%) as compared with the placebo
(56.5%). This investigator‑generated bias could distinctly
impact the PCTP outcome on two tiers. Firstly, the correctional factor of 2.3 may have led to a disproportionate decrease
in the number of biopsy recommendations in the finasteride
treatment group and delayed the diagnosis of prostate cancer.
Secondly, an increased proportion of biopsies, prompted by
an abnormal digital rectal examination, may have led to an
increased number of diagnoses of high‑grade cancers as previously established (24). In retrospect, it may have been more
useful to use the correction factor of 2 for serum PSA levels in
the finasteride‑treated patients. This would have more closely
simulated clinical practice while potentially avoiding the
aforementioned selection biases.
There was potential selection bias in the REDUCE trial.
A higher number of patients were diagnosed with prostate
cancer at the 1‑2 year mark in the placebo group and were
therefore removed from the study. A proportion of these
patients with initial low‑grade (Gl 5‑6) tumors may have
progressed to higher grade (Gl 7‑10) if left in the study
and re‑biopsied. One smaller study showed a significant
number of tumors that increased in grade over a similar time
interval (25). Should these results provide a direct translation into the REDUCE trial, it is unlikely that a significant
increase in the number of high‑grade tumors would have
been found in the treatment arm.
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Table I. Design comparison of the PCPT and the REDUCE trial.

Publication date
Designed length of study (years)
5α-reductase inhibitor
Cancer risk in cohort
Biopsy prior to study
Number enrolled
Number randomized
Number in final analysis
PSA correction factor
Decision for biopsy
Median number of biopsy cores
Overall incidence of prostate cancer (%)
Overall relative risk reduction (%)
Concern for increased risk of HG tumors

PCPT

REDUCE

7/2003
7
Finasteride (Proscar)
Low risk
(PSA <3, normal DRE)
No
24,482
18,882
9060
2.3
PSA >4, abnormal DRE
and at end of study
6
21.5
24.8
6.4% of patients with Gl 7-10 in
treatment arm compared to 5.1%
in placebo arm

4/2010
4
Dutasteride (Avodart)
Higher risk
(PSA 2.5-10)
Yes
8,231
8,122
6,706
2
Protocol at 2 and 4 years
10
22.5
22.8
12 Gl 8-10 tumors in treatment arm in
years 3-4 compared to only 1 in placebo
arm in years 3-4

PCPT, Prostate Cancer Prevention Trial; REDUCE, Reduction by Dutasteride of Prostate Cancer Events Trial; PSA, prostate‑specific antigen;
DRE, digital rectal examination; HG, high grade; Gl, Gleason score.

Both PCPT and REDUCE used prostate cancer incidence
as a primary endpoint. One recent study used data from the
Prostate, Lung, Colorectal and Ovarian trial to predict prostate
cancer mortality using prostate cancer incidence data from
the PCPT and REDUCE trials (26). Prognostic data, such
as Gleason score, PSA and clinical staging from each study
were used, as were aforementioned adjusted results from
PCPT based on increased sensitivity of prostate biopsy from
a decreased prostate volume. These results showed no significant differences in prostate cancer mortality in these studies,
with a trend towards an increased risk using the original PCPT
date, and a trend towards decreased risk using the adjusted
PCPT and REDUCE data. These data were corroborated by
a more recent updated analysis of patients from the PCPT,
which showed no significant differences in overall survival
between the placebo and treatment groups (27).
Perhaps the most compelling evidence that the observed
increased incidence of high‑grade prostate cancer is unrealistic stems from a study estimating the number of high‑grade
tumors if all the patients with a positive biopsy had undergone
a prostatectomy (19). Data from 500 patients who underwent
a prostatectomy of the 2,017 patients diagnosed with prostate
cancer in PCPT were analyzed, towards a model development to evaluate factors increasing the odds of undergoing
a prostatectomy and subsequent risk of these patients having
high‑grade disease. Issues of selection bias become quickly
apparent, as noted by the authors; the patients who underwent a
prostatectomy were not a random sample. A younger age, PSA
at randomization and biopsy prompted by PSA or DRE were
all positive predictors of a prostatectomy. These patients were
also more likely to be diagnosed with prostate cancer on ‘for

cause’ biopsies with a longer time observed after diagnosis.
Upon factoring in this bias, the adjusted results of the PCPT
are encouraging. The estimation of prostate cancer prevalence
showed a decreased risk of overall and high‑grade disease in
the finasteride arm as compared with the placebo, resulting
in a 27% relative risk reduction for high‑grade tumors (95%
confidence interval, 0.56‑0.96; P=0.02) (19).
4. Future REDEEM‑ing of 5α‑reductase inhibition
It is important to determine where these discussed considerations may lead. Both the PCPT and REDUCE trials unfolded
a provocative data in the analysis of prostate cancer chemopreventative strategies. Table I summarizes key similarities
and differences between the two trials. The PCPT was a larger
study that was comprised of patients with much lower baseline
PSA and normal DRE, and no previous biopsies. The results
revealed a decreased number of patients diagnosed with prostate cancer in the finasteride group. Of those patients, however,
there was a significant increase in the number of higher‑grade
tumors as compared with the placebo. The REDUCE trial was
designed to evaluate patients with an increased risk of prostate
cancer, based on elevated PSA, and with recent prior negative
prostate biopsy. The majority of biopsies (93%) were scheduled
accordingly to eliminate clinician‑generated biases, based on
rectal examination and PSA. Mirroring the outcomes of the
PCPT trial, REDUCE also revealed a significant decrease
in prostate cancer incidence in the treatment arm, and an
increased number of high‑grade tumors following treatment.
The significant decrease in prostate cancer prevalence in
both the PCPT and REDUCE trials raises hope for potential
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chemoprevention agents in the fight against prostate cancer.
This emerges as an increasingly important argument with the
changing landscape of medicine and the intense scrutiny over
the diagnosis and treatment of prostate cancer. The acceptance
for the use of 5α‑RIs in prostate cancer chemoprevention is
the notion of their potential effect in predisposing patients
to high‑grade prostate cancer. This is an unfortunate consequence from the over‑interpretation of findings from the PCPT
and REDUCE trials. Numerous mathematical models reflect
with confidence that 5α‑RIs are not likely to increase risk for
high‑grade prostate cancer, and significantly enough others
predict an actual reduced risk for all grades of prostate cancer
by these agents (19,21‑23). Furthermore, follow‑up data from
the REDUCE trial following an additional 2 years, showed no
new Gleason 8‑10 tumors (28). Despite the strong collective
evidence towards a chemoprevention action that can be clinically exploited, support has not been sufficiently powerful for
the Food and Drug Administration's Oncologic Drug Advisory
Committee to approve the use of 5α‑RIs for prostate cancer
chemoprevention (29).
Besides the potential for chemoprevention, the therapeutic
value of 5α‑RIs has also been interrogated in the treatment of
prostate cancer during the progression to an advanced disease.
The REDEEM trial revealed great promise that dutasteride
may decrease the progression of low‑grade prostate cancer in
men undergoing active surveillance (30). Additional ongoing
trials are pursuing the potential therapeutic value of 5α‑RIs
in patients facing biochemical failure following definitive
therapy and adjuvant therapy with bicalutamide in castration‑resistant prostate cancer. One could easily argue that
there is a subset of patients who would benefit from 5α‑RI
treatment, depending on the cellular landscape of individual
tumors, but this subset requires stringent profiling, without
factoring in cost‑effectiveness. Kattan et al (31) reported that
dutasteride may be cost‑effective as a chemoprevention agent,
but only in patients at high‑risk for prostate cancer diagnosis.
Reports by an independent investigative team, however,
sharply challenged the cost‑effectiveness of finasteride, based
on survival and quality of life as outcomes of success (32).
As controversy still surrounds the value of the 5α‑RIs in
impairing prostate cancer, additional studies are warranted to
determine a safe, efficacious, cost‑effective chemopreventive
agent to be given to young men, for preventing the disease in
the ageing population. The non‑biased counseling of patients
on the risks and benefits associated with the 5α‑reductase
inhibitors and their potential for chemoprevention of prostate
cancer is built on the clinical impact of the two trials, PCTP
and REDUCE.
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